EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review

Mohamed Abdalbary, Ahmed Mazen Amin, Ahmed Elaraby, Ahmed Hassan

Osteoporosis International · 2026-02 · 37 (2) · 319-329

DOI: 10.1007/s00198-025-07707-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Osteoporosis International, online erschienen am 31.10.2025. Verfasst von Mohamed Abdalbary und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology and Dialysis Unit, Internal Medicine Department Faculty of Medicine Dakahlia Governorate, Mansoura University, 1 El Gomhouria St, Mansoura…. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Osteoporosis, Bone Density Conservation Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mansoura University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is an independent risk factor for osteoporosis. Managing bone loss in CKD patients involves both non-pharmacological and pharmacological strategies. Romosozumab, a monoclonal antibody that targets sclerostin, represents a major advancement in osteoporosis treatment. Recent studies showed that the majority of patients with early stages of CKD tend to have low bone turnover. The dual romosozumab mechanism of suppressing bone resorption and augmenting bone formation could be helpful in those patients. However, the concerns about increasing vascular calcification need to be clarified. This review explores the effects of osteoporosis on CKD patients, detailing its pathogenesis especially the role of adynamic bone disease, shedding light on Wnt pathways and their influence on bone turnover and vascular calcifications. Lastly, we provide an in-depth overview of romosozumab and its effectiveness and reported safety in treating patients with CKD and osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicOsteoporosisBone Density Conservation AgentsAntibodies, MonoclonalHumansBone RemodelingAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

Bone mineral densityChronic kidney diseaseLow bone turnoverOsteoporosisRomosozumabVascular calcification

Substanzen

romosozumabBone Density Conservation AgentsAntibodies, MonoclonalSOST protein, humanAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Nephrology and Dialysis Unit, Internal Medicine Department Faculty of Medicine Dakahlia Governorate, Mansoura University, 1 El Gomhouria St, Mansoura, 35516, Egypt. dr.mo7a.m@mans.edu.eg.
  • Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Department of Cardiology, Suez Medical Complex, Ministry of Health and Population, Suez, Egypt.

Förderung

  • Mansoura University

Zitieren

APA

Abdalbary, M., Amin, A. M., Elaraby, A., & Hassan, A. (2026). Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review. Osteoporosis International, 37(2), 319-329. https://doi.org/10.1007/s00198-025-07707-7

Vancouver

Abdalbary M, Amin AM, Elaraby A, Hassan A. Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review. Osteoporosis International. 2026;37(2):319-329. doi:10.1007/s00198-025-07707-7

BibTeX
@article{Abdalbary2026,
  author = {Abdalbary, Mohamed and Amin, Ahmed Mazen and Elaraby, Ahmed and Hassan, Ahmed},
  title = {Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review},
  journal = {Osteoporosis International},
  year = {2026},
  volume = {37},
  number = {2},
  pages = {319--329},
  doi = {10.1007/s00198-025-07707-7}
}
Kostenlos starten →